Quest Diagnostics Incorporated (DGX)
After hours:
| Previous close | 130.09 |
| Open | 135.00 |
| Bid | 136.00 x 800 |
| Ask | 137.15 x 800 |
| Day's range | 133.11 - 138.91 |
| 52-week range | 119.59 - 148.62 |
| Volume | |
| Avg. volume | 1,051,595 |
| Market cap | 15.181B |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | 18.25 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.00 (2.31%) |
| Ex-dividend date | 05 Apr 2024 |
| 1y target est | N/A |
- PR Newswire
Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024
Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2024.
- PR Newswire
Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced the launch of a new blood biomarker test for phosphorylated tau 217, or p-tau217. P-tau217 is a biomarker associated with Alzheimer's Disease (AD), supported by research as useful for an early diagnosis of AD.
- PR Newswire
Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and Broad Clinical Labs, the world expert in whole genome sequencing (WGS), today announced a research collaboration designed to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.
